AI IntelligenceMar 23, 2026M&A
Article
Gilead Sciences -> Unbenannte Autoimmun-Biotech-Firma
Gilead Sciences is nearing a deal worth up to $2 billion to acquire an unnamed biotech company focused on autoimmune diseases. The California-based drugmaker is taking advantage of its surging share price to strike takeovers after a quiet couple of years. The target likely utilizes AI-powered drug discovery platforms.
Data Cube AI EditorialSource: Financial Times
01
Source Brief
Gilead Sciences is nearing a deal worth up to $2 billion to acquire an unnamed biotech company focused on autoimmune diseases. The California-based drugmaker is taking advantage of its surging share price to strike takeovers after a quiet couple of years. The target likely utilizes AI-powered drug discovery platforms.